Supplementary Figures 1-8, Supplementary Tables 1-3 from BRAF Inhibitors Amplify the Proapoptotic Activity of MEK Inhibitors by Inducing ER Stress in NRAS-Mutant Melanoma
Year: 2023
Type: supplementary-materials
Abstract: Suppl. Figure 1 Encorafenib combined with binimetinib leads to increased growth inhibition and increased induction of apoptosis in NRAS-mutant melanoma cells Suppl. Figure 2 The panRAF inhibitor Raf265 combined with binimetinib leads to growth inhibition, induction of apoptosis and ER stress genes in NRAS-mutant melanoma cells Suppl. Figure 3 Dabrafenib combined with trametinib leads to strong growth inhibition, induction of apoptosis and ER stress genes in NRAS-mutant melanoma cells Suppl. Figure 4 In normal skin cells encorafenib and binimetinib induce only weak growth inhibition and no significant levels of apoptosis Suppl. Figure 5 BRAFi combined with MEKi leads to an ER stress response involving the PERK pathway? Suppl. Figure 6 BRAFi combined with MEKi leads to activation of PUMA in patient-derived tumor slice cultures. Suppl. Figure 7 Binimetinib and encorafenib induced apoptosis is partly mediated by the anti-apoptotic BCL-2 family members and by the pro-apoptotic BH3-only protein NOXA . Suppl. Figure 8 NRAS mutated cells resistant to encorafenib, binimetinib or the combination of encorafenib and binimetinib.
Language: English
Topic: Melanoma and MAPK Pathways
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: gold
OpenAlex ID: W4361922586